Guangzhou Wondfo Biotech Co.,Ltd (SHE: 300482)

Market Cap	9.77B
Revenue (ttm)	2.85B
Net Income (ttm)	508.92M
Shares Out	478.30M
EPS (ttm)	1.13
PE Ratio	18.11
Forward PE	13.13
Dividend	0.40 (1.93%)
Ex-Dividend Date	Jun 5, 2024

Volume	1,413,300
Open	21.24
Previous Close	20.75
Day's Range	20.69 - 21.24
52-Week Range	20.52 - 32.64
Beta	0.61
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 25, 2024

About Guangzhou Wondfo Biotech Co.,Ltd

Guangzhou Wondfo Biotech Co.,Ltd, an in vitro diagnostics company, engages in the research and development, production, and sale of point-of-care testing products, and rapid diagnosis and chronic disease management solutions in China. The company offers rapid test kits for COVID-19, drug of abuse, tumor, infectious, fertility, and sexually transmitted diseases, as well as immunofluorescence devices to detect cardiovascular diseases, inflammation, kidney injury, sex hormones, thyroid function, diabetes, tumor, and other diseases. It also provide...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1992
• Employees: 3,404
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 300482

Financial Performance

In 2023, Guangzhou Wondfo Biotech Co.,Ltd's revenue was 2.76 billion, a decrease of -51.33% compared to the previous year's 5.68 billion. Earnings were 487.62 million, a decrease of -59.26%.